Challenges and Prospects for Eradication of Helicobacter pylori: Targeting Virulence Factors, Metabolism, and Vaccine Innovation
Pathogens · 2025
DOI: 10.3390/pathogens14070619 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathogens, 2025. Verfasst von Adrian Bakiera und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Microbiology, Medical University of Lublin, 20-093 Lublin, Poland. Hauptthemen laut MEDLINE: Helicobacter pylori, Helicobacter Infections, Virulence Factors, Bacterial Vaccines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lublin, Poland.
Abstract (Originalsprache)
Helicobacter pylori is a Gram-negative bacterium that infects almost half of the global population and is linked to gastric conditions like peptic ulcers and gastric cancer, as well as other diseases such as neurological disorders, cardiovascular problems, and iron deficiency anemia. Its survival in the acidic stomach environment is due to virulence factors like urease, flagella, and adhesion proteins (BabA, SabA). Current treatments involve a combination of antibiotics (clarithromycin, metronidazole, amoxicillin, tetracycline) and proton pump inhibitors, but increasing antibiotic resistance, especially to clarithromycin and metronidazole, poses a major challenge. Resistance mechanisms include mutations in drug targets, efflux pump overexpression, and enzymatic degradation of antibiotics. This has prompted exploration of alternative therapies targeting bacterial processes like urease activity, biofilm formation, and metabolic pathways (energy production, amino acid synthesis, iron acquisition). Natural compounds, such as chitosan and plant extracts, show promise in combating H. pylori growth and virulence. Vaccine development is also ongoing, with DNA vaccines showing potential for broad immune responses. However, no vaccine is yet close to widespread clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Microbiology, Medical University of Lublin, 20-093 Lublin, Poland.
- Stefan Cardinal Wyszynski District Specialist Hospital, 20-718 Lublin, Poland.
- Department of Gastroenterology with Endoscopic Unit, Medical University of Lublin, 20-953 Lublin, Poland.
ORCID-Profile: Adrian Bakiera, Anita Solarz, Izabela Korona-Głowniak
Förderung
- Medical University of Lublin, Poland
Zitieren
APA
Bakiera, A., Solarz, A., Kowalczyk, M., Cichoż-Lach, H., & Korona-Głowniak, I. (2025). Challenges and Prospects for Eradication of Helicobacter pylori: Targeting Virulence Factors, Metabolism, and Vaccine Innovation. Pathogens. https://doi.org/10.3390/pathogens14070619
Vancouver
Bakiera A, Solarz A, Kowalczyk M, Cichoż-Lach H, Korona-Głowniak I. Challenges and Prospects for Eradication of Helicobacter pylori: Targeting Virulence Factors, Metabolism, and Vaccine Innovation. Pathogens. 2025. doi:10.3390/pathogens14070619
BibTeX
@article{Bakiera2025,
author = {Bakiera, Adrian and Solarz, Anita and Kowalczyk, Marika and Cichoż-Lach, Halina and Korona-Głowniak, Izabela},
title = {Challenges and Prospects for Eradication of Helicobacter pylori: Targeting Virulence Factors, Metabolism, and Vaccine Innovation},
journal = {Pathogens},
year = {2025},
doi = {10.3390/pathogens14070619}
}
EUVIMED